MXPA03001777A - Derivados de quinazolina como antagonistas adrenergicos alfa-1. - Google Patents
Derivados de quinazolina como antagonistas adrenergicos alfa-1.Info
- Publication number
- MXPA03001777A MXPA03001777A MXPA03001777A MXPA03001777A MXPA03001777A MX PA03001777 A MXPA03001777 A MX PA03001777A MX PA03001777 A MXPA03001777 A MX PA03001777A MX PA03001777 A MXPA03001777 A MX PA03001777A MX PA03001777 A MXPA03001777 A MX PA03001777A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- quinazoline derivatives
- adrenergic antagonists
- adrenergic
- antagonists
- Prior art date
Links
- 239000000674 adrenergic antagonist Substances 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22950300P | 2000-08-31 | 2000-08-31 | |
| PCT/EP2001/009749 WO2002018348A2 (en) | 2000-08-31 | 2001-08-23 | Quinazoline derivatives as alpha-1 adrenergic antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03001777A true MXPA03001777A (es) | 2003-06-04 |
Family
ID=22861517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03001777A MXPA03001777A (es) | 2000-08-31 | 2001-08-23 | Derivados de quinazolina como antagonistas adrenergicos alfa-1. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6559153B2 (es) |
| EP (1) | EP1315714B1 (es) |
| JP (1) | JP3971299B2 (es) |
| KR (1) | KR100602929B1 (es) |
| CN (1) | CN1308324C (es) |
| AR (1) | AR032475A1 (es) |
| AT (1) | ATE309240T1 (es) |
| AU (2) | AU2001293788B2 (es) |
| BR (1) | BR0113585A (es) |
| CA (1) | CA2420177C (es) |
| DE (1) | DE60114852T2 (es) |
| ES (1) | ES2251512T3 (es) |
| GT (1) | GT200100181A (es) |
| MX (1) | MXPA03001777A (es) |
| PA (1) | PA8527901A1 (es) |
| PE (1) | PE20020407A1 (es) |
| UY (1) | UY26919A1 (es) |
| WO (1) | WO2002018348A2 (es) |
| ZA (1) | ZA200301082B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500373A (ja) * | 2001-08-10 | 2005-01-06 | ポリチップ ファーマスーティカルズ プロプライエタリイ リミテッド | モルヒネ様オピオイド化合物の誘導体 |
| ATE521593T1 (de) * | 2002-04-03 | 2011-09-15 | Orion Corp | Verwendung eines alfa2-adrenorezeptorantagonisten bei mit dem zns zusammenhängenden erkrankungen |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| ITMI20030151A1 (it) * | 2003-01-30 | 2004-07-31 | Recordati Ind Chimica E Farma Ceutica S P A | Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore. |
| EP1646615B1 (en) * | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| CN1829708A (zh) * | 2003-07-24 | 2006-09-06 | 尤罗塞尔蒂克股份有限公司 | 哌啶化合物和含有它们的药物组合物 |
| WO2006021345A2 (en) * | 2004-08-27 | 2006-03-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b) |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US7344583B2 (en) * | 2005-03-31 | 2008-03-18 | 3M Innovative Properties Company | Methods of making metal particles within cored dendrimers |
| US7413607B2 (en) * | 2005-03-31 | 2008-08-19 | 3M Innovative Properties Company | Templated semiconductor particles and methods of making |
| ES2334708T3 (es) * | 2005-05-04 | 2010-03-15 | F. Hoffmann-La Roche Ag | (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht. |
| JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2008036700A2 (en) * | 2006-09-19 | 2008-03-27 | 3M Innovative Properties Company | Templated metal oxide particles and methods of making |
| JP4705695B2 (ja) | 2007-10-11 | 2011-06-22 | アストラゼネカ アクチボラグ | プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体 |
| TW200944526A (en) * | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| PH12013502048B1 (en) | 2011-04-01 | 2018-07-11 | Astrazeneca Ab | Therapeutic treatment |
| AU2012321110B2 (en) | 2011-11-30 | 2014-10-23 | Astrazeneca Ab | Combination treatment |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| CN110662541B (zh) * | 2017-03-12 | 2023-02-10 | 王晓冬 | 多环胺作为阿片受体调节剂 |
| WO2019088095A1 (ja) * | 2017-11-02 | 2019-05-09 | 国立大学法人九州大学 | 鎮痛剤及びその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997011698A1 (en) | 1995-09-29 | 1997-04-03 | Merck & Co., Inc. | ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| US6355641B1 (en) | 1999-03-17 | 2002-03-12 | Syntex (U.S.A.) Llc | Oxazolone derivatives and uses thereof |
-
2001
- 2001-08-23 DE DE60114852T patent/DE60114852T2/de not_active Expired - Fee Related
- 2001-08-23 BR BR0113585-6A patent/BR0113585A/pt not_active IP Right Cessation
- 2001-08-23 CA CA002420177A patent/CA2420177C/en not_active Expired - Fee Related
- 2001-08-23 AU AU2001293788A patent/AU2001293788B2/en not_active Ceased
- 2001-08-23 EP EP01974210A patent/EP1315714B1/en not_active Expired - Lifetime
- 2001-08-23 MX MXPA03001777A patent/MXPA03001777A/es active IP Right Grant
- 2001-08-23 ES ES01974210T patent/ES2251512T3/es not_active Expired - Lifetime
- 2001-08-23 AT AT01974210T patent/ATE309240T1/de not_active IP Right Cessation
- 2001-08-23 KR KR1020037002933A patent/KR100602929B1/ko not_active Expired - Fee Related
- 2001-08-23 WO PCT/EP2001/009749 patent/WO2002018348A2/en not_active Ceased
- 2001-08-23 AU AU9378801A patent/AU9378801A/xx active Pending
- 2001-08-23 CN CNB018165958A patent/CN1308324C/zh not_active Expired - Fee Related
- 2001-08-23 JP JP2002523466A patent/JP3971299B2/ja not_active Expired - Fee Related
- 2001-08-29 PE PE2001000870A patent/PE20020407A1/es not_active Application Discontinuation
- 2001-08-29 US US09/942,385 patent/US6559153B2/en not_active Expired - Fee Related
- 2001-08-30 GT GT200100181A patent/GT200100181A/es unknown
- 2001-08-30 AR ARP010104130A patent/AR032475A1/es unknown
- 2001-08-30 PA PA20018527901A patent/PA8527901A1/es unknown
- 2001-08-30 UY UY26919A patent/UY26919A1/es not_active Application Discontinuation
-
2003
- 2003-02-07 ZA ZA200301082A patent/ZA200301082B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR032475A1 (es) | 2003-11-12 |
| ZA200301082B (en) | 2004-05-07 |
| AU9378801A (en) | 2002-03-13 |
| DE60114852T2 (de) | 2006-07-27 |
| US6559153B2 (en) | 2003-05-06 |
| GT200100181A (es) | 2002-05-23 |
| EP1315714B1 (en) | 2005-11-09 |
| CN1545510A (zh) | 2004-11-10 |
| WO2002018348A2 (en) | 2002-03-07 |
| CN1308324C (zh) | 2007-04-04 |
| KR100602929B1 (ko) | 2006-07-20 |
| KR20030022421A (ko) | 2003-03-15 |
| US20020045614A1 (en) | 2002-04-18 |
| WO2002018348A3 (en) | 2002-07-11 |
| ATE309240T1 (de) | 2005-11-15 |
| JP3971299B2 (ja) | 2007-09-05 |
| EP1315714A2 (en) | 2003-06-04 |
| CA2420177A1 (en) | 2002-03-07 |
| CA2420177C (en) | 2008-07-08 |
| JP2004507527A (ja) | 2004-03-11 |
| UY26919A1 (es) | 2002-02-28 |
| BR0113585A (pt) | 2003-07-29 |
| AU2001293788B2 (en) | 2007-10-11 |
| PA8527901A1 (es) | 2002-07-30 |
| PE20020407A1 (es) | 2002-05-21 |
| ES2251512T3 (es) | 2006-05-01 |
| DE60114852D1 (de) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03001777A (es) | Derivados de quinazolina como antagonistas adrenergicos alfa-1. | |
| MXPA03005854A (es) | Derivados de quinazolona como antagonistas del receptor adrenergico alfa 1a/b. | |
| MXPA03000738A (es) | Antagonistas de grelina. | |
| ZA200108868B (en) | Piperazine derivatives useful as CCR5 antagonists. | |
| ZA200307646B (en) | Benzamidine derivative. | |
| IL154131A0 (en) | Quinazoline derivatives | |
| ZA200204395B (en) | Selective neurokinin antagonists. | |
| ZA200207331B (en) | Ethylenediamine derivatives. | |
| MXPA03000939A (es) | Derivados de imidazol. | |
| MXPA03004527A (es) | Compuestos antagonicos lfa-1. | |
| IL162377A0 (en) | 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists | |
| ZA200202775B (en) | Quinazoline derivatives as VEGF inhibitors. | |
| PL362900A1 (en) | Piperazine derivatives as 5-ht1b antagonists | |
| IL150550A0 (en) | 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists | |
| MXPA03006991A (es) | Derivados de piperidina como antagonistas de neurocinina 1. | |
| MXPA03008338A (es) | Derivados de piperazina. | |
| AU2001234741A1 (en) | Integrin antagonists | |
| MXPA03004136A (es) | Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy). | |
| ZA200110127B (en) | Substituted benzimidazole. | |
| ZA200205482B (en) | Aminosulfonylbiphenyl derivatives. | |
| ZA200206151B (en) | Substituted amionomethyl-phenyl-cyclohexane derivatives. | |
| MXPA03004453A (es) | Derivados de pirimidina. | |
| PL351616A1 (en) | Polyolefin compositions, method for the production and use thereof | |
| MXPA03002737A (es) | Derivados sustituidos de 1-aminobutan-3-ol. | |
| ZA200206150B (en) | Aminomethyl-phenyl-cyclohexanone derivatives. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |